Key Highlights

  • Revenue from ordinary activities increased 5.8% to $1,592,255, compared with $1,505,064 in FY25
  • Loss from ordinary activities after tax rose 461.7% to $8,524,468, compared with $1,517,753 in FY25
  • Net Assets increased by $1,499,730 to $4,335,386, primarily from Capital raisings completed during the year
  • The company completed a $5.0 million strategic Placement to advance its RRAM, neuromorphic, sensor and robotics programs

Shares in dorsaVi Limited (ASX:DVL) fell 4.17% to $0.023 on 3 September 2026, down 0.1 cents, as at 11:48am AEST. The decline might follows the release of the company's results for the year ended 30 June 2026, which showed a substantial increase in its net loss alongside modest Revenue growth.

Financial Performance

dorsaVi reported total revenue and other income of approximately $1.59 million for FY26, compared with $1.51 million in the previous financial year, an increase of 5.8%. Within this, sales revenue was $1.00 million, down from $1.13 million in the prior period, which the company attributed to the timing of customer projects and an ongoing transition toward larger commercial relationships.

The Group recorded a loss after tax of $8.52 million for FY26, compared with a loss of $1.52 million in FY25, an increase of 461.7%. The company stated the reported loss includes the effect of increased Investment in its technology and intellectual property portfolio, expansion of its semiconductor development activities, share-based payments, and Amortisation of acquired intangible assets. The company noted that the majority of its costs during the year remained consistent with the previous financial year.

Balance Sheet and Capital Raising

During the financial year, the consolidated entity increased its net assets by $1,499,730 to $4,335,386, up from $2,835,656 at 30 June 2025. The company attributed the main increase in net assets to capital raisings completed during the financial year, including a $5.0 million strategic placement supported by new and existing sophisticated and professional investors.

At 30 June 2026, the Group held approximately $2.12 million in cash and reported net assets of approximately $4.34 million. The funds raised through the placement were directed toward advancing the company's RRAM, neuromorphic, sensor and robotics programs, together with general working capital. No dividends were paid, recommended or declared during the financial period.

Technology Programs and Priorities

The company's stated priorities for the year ahead include completing Manufacturing and electrical characterisation of its RRAM-CMOS validation chip, and using the resulting data to optimise the RRAM material stack, memory array and Compute-in-Memory architecture. dorsaVi also intends to advance its staged NTU–ITRI pathway toward a commercially relevant 22-nanometre RRAM platform and progress the integration and validation of its neuromorphic intellectual property.

On the commercial side, the company plans to commercialise its Sensor V6.5 product and expand its sensor Business through a distributor-led hybrid model, alongside developing strategic semiconductor, robotics and commercial partnerships. Management stated it remains focused on disciplined capital allocation, clearly defined technical milestones, and the development of commercial pathways capable of generating sustainable Shareholder value.

Conclusion

dorsaVi's FY26 results show a substantial widening of the company's net loss, driven by increased investment in its technology and semiconductor development programs, share-based payments and intangible asset amortisation, even as total revenue and other income grew modestly and sales revenue itself declined on the back of project timing and a shift toward larger commercial relationships. The improvement in net assets, supported by the $5.0 million capital placement, provides funding runway for the company's RRAM, neuromorphic, sensor and robotics initiatives heading into FY27. With several technical milestones flagged for the year ahead, including the RRAM-CMOS validation chip and the 22-nanometre platform pathway, the company's progress against these priorities will be a key determinant of its trajectory going forward.